Users Manual Part 1

Clinical User’s Guide IBA | xxi|
Volume 1 - Treatment Session
List of Published Literature
1. Exaggerated radiation-induced fibrosis in patients with systemic sclerosis.
Varga, J, et al. 24, Philadelphia : s.n., 1991, JAMA, Vol. 265, pp. 3292-3295.
2. Consequences of breast irradiation in patients with pre-existing collagen
vascular diseases. Fleck, R, et al. 4, Houston : s.n., 1989, Int J Radiat Oncol Biol
Phys, Vol. 17, pp. 829-833.
3. Acute and late reactions to radiation therapy in patients with collagen vascular
diseases. Ross, JG, et al. 11, Iowa City : s.n., 1993, Cancer, Vol. 71, pp. 3744-
3752.
4. Irradiation of the setting of collagen vascular disease: Acute and late
complications. Morris, MM et Powell, SN. 7, Boston : s.n., 1997, Journal of
Clinical Oncology, Vol. 15, pp. 2728-2735.
5. Severe acute toxicity from whole breast radiotherapy in the setting of collagen
vascular disease. Hernandez, S, Evans, SB et Wazer, DE. 6, Boston : s.n., 2006,
American Journal of Clinical Oncology, Vol. 29, pp. 647-648.
6. Radiotherapy in setting of collagen vascular disease. Wo, J et Taghian, A. 5,
Boston : s.n., 2007, Int J Radiat Oncol Biol Phys, Vol. 69, pp. 1347-1353.
7. Matched-control retrospective study of the acute and late complications in
patients with collagen vascular diseases treated with radiation therapy. Phan, C,
et al. Louisville : s.n., 2003, Cancer.
8. Role of radiation therapy in patients with a diagnosis of both systemic lupus
erythematosus and cancer. Benk, V, et al. 1, Toronto : s.n., 2005, Arthritis &
Rheumatism, Vol. 53, pp. 67-72.
9. Systemic lupus erythematosus, radiotherapy, and the risk of acute and chronic
toxicity: The Mayo Clinic Experience. Pinn, ME, et al. 2, Rochester : s.n., 2008,
Int J Radiat Oncol Biol Phys, Vol. 71, pp. 498-506.
10. Ataxia Telangiectasiae - Mutated gene polymorphisms and acute normal tissue
injuries in cancer patients after RT. Dong, L, et al. 5, Changchun : s.n., 2014, Int
J Radiat Oncol Biol Phys, Vol. 91, pp. 1090-1098.
11. Relative biological effectiveness values for proton beam therapy. Variations as a
function of biological endpoint, dose, and linear energy transfer. Paganetti, H, et
al. 22, Boston : s.n., 2014, Physics in Medicine & Biology, Vol. 59, pp. 420-473.
12. Towards achieving the full clinical potential of proton therapy by inclusion of LET
and RBE models. Jones, B. Oxford : s.n., 2015, Cancers, Vol. 7, pp. 460-480.
13. Clinical evidence of variable proton biological effectiveness in pediatric patients
treated for ependymoma. Peeler, CR, et al. Houston : s.n., 2016, Radiotherapy
and Oncology, pp. 395-401.
14. Disregarding RBE variation in treatment plan comparison may lead to bias in
favor of proton plans. Wedenberg, M et Toma-Dasu, I. 9, Stockholm : s.n., 2014,
Medical Physics, Vol. 41.